Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment

@inproceedings{Yeku2017ArmoredCT,
  title={Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment},
  author={Oladapo O. Yeku and Terence J. Purdon and Mythili Koneru and David R. Spriggs and Renier J. Brentjens},
  booktitle={Scientific Reports},
  year={2017}
}
Chimeric antigen receptor (CAR) T cell therapy has shown limited efficacy for the management of solid tumor malignancies. In ovarian cancer, this is in part due to an immunosuppressive cytokine and cellular tumor microenvironment which suppresses adoptively transferred T cells. We engineered an armored CAR T cell capable of constitutive secretion of IL-12, and delineate the mechanisms via which these CAR T cells overcome a hostile tumor microenvironment. In this report, we demonstrate enhanced… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 71 times over the past 90 days. VIEW TWEETS
7 Citations
59 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 59 references

Phase I Trial of AntiPSMA Designer CART Cells in Prostate Cancer : Possible Role for Interacting Interleukin 2T Cell Pharmacodynamics as a Determinant of Clinical Response

  • R. P. Junghans
  • Prostate
  • 2016

Possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical Response

  • Junghans, R. P. et al. Phase I Trial of Anti-PSMA Designer CAR- Cancer
  • Prostate 76, 1257–70
  • 2016

Role of the immune system in the peritoneal tumor spread of high grade serous ovarian cancer

  • K Auer
  • Oncotarget 7,
  • 2016

utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell antitumour efficacy

  • O. O. Yeku, Brentjens, R. J. Armored CAR T-cells
  • Biochem. Soc. Trans. 44, 412–8
  • 2016

Similar Papers

Loading similar papers…